Photo: markets.businessinsider.com
Johnson & Johnson's Nipocalimab Shows Promise in Sjogren's Disease Study
Johnson & Johnsons investigational drug nipocalimab shows significant promise in reducing disease activity in Sjögren syndrome, as reported in a Phase 2 study published in The Lancet.
- The Phase 2 DAHLIAS study, published in The Lancet, found that nipocalimab significantly decreased disease activity in patients with moderate-to-severe Sjögren syndrome at Week 24.
- Patients receiving nipocalimab 15 mg/kg Q2W demonstrated statistically significant improvements in the ClinESSDAIa score compared to the placebo group, indicating a promising treatment option.
- The studys findings suggest that targeting the neonatal Fc receptor may offer new hope for patients suffering from fatigue and other debilitating symptoms associated with Sjögren syndrome.
Why It Matters
This research by Johnson & Johnson could reshape treatment approaches for Sjögren syndrome, a condition often overlooked in autoimmune research. The promising results also highlight the potential for innovative therapies targeting the neonatal Fc receptor, potentially leading to FDA approval and better patient outcomes.